Skip to main content
Figure 3 | BMC Endocrine Disorders

Figure 3

From: Q-Score: development of a new metric for continuous glucose monitoring that enables stratification of antihyperglycaemic therapies

Figure 3

Individual improvement potential demonstrated for three CGM profiles. Values for the Q-Score parameters, and the individual improvement potential for each Q-Score parameter are demonstrated for three historic CGM curves. (A) The CGM profile (#128830) was recorded in a 75-year-old individual, diagnosed at age 56 (BMI 21.6 kg/m2, recorded HbA1c 7.5%). The subject was treated with intensified conventional therapy (ICT) (prandial insulin: 5, 5, 3, 3 IU; basal insulin: 5, 6 IU). (B) The CGM profile (#133657) was obtained from a 53-year-old individual, diagnosed at age 46. (BMI 32.3 kg/m2, recorded HbA1c 6.8%). The subject was treated with oral hypoglycaemic agents (metformin 1 × 850 mg, sulfonylurea 2 × 1.75 mg). (C) The CGM profile (#136516) was recorded in a 75-year-old individual, diagnosed at age 52 (BMI 29.7 kg/m2, recorded HbA1c 8.6%). The subject was treated with a combination of oral hypoglycaemic agents (metformin 2 × 1000 mg) and insulin (ICT: 28, 26 and 26 IU; basal insulin 40 IU).

Back to article page